Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib Combinations in Early-stage, PIK3CA-Mutated Breast Cancer
NCT07054190Phase 2Recruiting
- Sponsor
- Roche
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of inavolisib in breast cancer, sponsored by Roche. Started Sep 2025; status: recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07054190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07054190.